New combo pills for high blood pressure under Real-World study

NCT ID NCT05413057

Recruiting now Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large observational study will follow 20,000 adults with essential hypertension who are prescribed one of two combination pills containing fimasartan. The main goal is to see how well these pills control blood pressure over 12 weeks, and a longer follow-up of up to 2 years will check for heart events and safety. Participants take their medication as part of routine care, and researchers collect data on effectiveness and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide (single-pill combinations)
What this could lead to: If successful, this study could confirm that these combination pills effectively control blood pressure and reduce long-term heart risks in people with essential hypertension.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. Side effects are possible, and the 12-week main phase is too short to assess long-term safety or outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION,ESSENTIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension essential hypertension, genetic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION,ESSENTIAL

Contacts and locations

Locations

Seoul National University Bundang Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.